The date revealed that AML patients with FLT3 or DNMT3A (not shown) mutations overexpressed CD44v6 compared to healthy donors, which was consistent with the results of the SKM‐1 cells with FLT3 mutation or DNMT3A mutation (Figure 1F). This evidence concerns the gene DNMT3A and acute myeloid leukemia.